Prostate Cancer’s Precision Promise


Event Details


Oslo Cancer Cluster invites you to the symposium “Prostate Cancer’s Precision Promise”. Prostate Cancer is the most common cancer to effect men. The clumps of cancerous cells on the walnut-shaped prostate are slow to grow and are prone to spread to form a more aggressive deadly version. In this symposium, you will hear about the advances in the promise of precision cancer medicine that will be able to pair interdisciplinary data to provide better and more efficient treatment for cancer.

This symposium includes a networking session focusing on Horizon 2020 funding opportunities for both academia and industry in the field of cancer and personalised medicine.

 

Registration

This event is FREE to attend. Please register by completing the form at the end of this page.

 

This symposium is supported by:

 

AGENDA:

09:00–09:15 Registration and Light Refreshments
09:15–09:30 Welcome and Introduction
09:30–10:10 Extracellular Vesicles as Biomarkers and Disease Mediators: A Case for Multi-omics in Prostate Cancer Precision Medicine

Prof. Michelle Hill, QIMR Berghofer Medical Research Institute, The University of Queensland, Australia

10:10–10:50 The Value of Quantitative Proteomics for Precision Medicine in Prostate Cancer

Prof. Diego Iglesias-Gato, University of Copenhagen, Denmark

10:50–11:10 Coffee Break
11:10–11:50 Molecular Tests to Improve Precision Medicine in Prostate Cancer

Prof. Kristin Austlid Taskén, Oslo University Hospital, Norway

11:50–12:30 The National Prostate Cancer Registry: Results, Available Data for Research and Future Direction

Dr. Tom Børge Johannesen, Cancer Registry of Norway, Norway

12:30–13:00 NETWORKING LUNCH

Horizon 2020 – Cancer and Personalised Medicine

Dr. Gupta Udatha, Oslo Cancer Cluster, Norway

13:00–13:30 Logistics Innovation in Cancer Medicine

Mr. Raphael Grill, Kuehne+Nagel, Norway

 

For sponsorship opportunities and further queries, please contact either Gupta Udatha (or) Charlotte Wu Homme

Registration

Print This Post